Ligand Pharmaceuticals (LGND) Cash & Equivalents (2010 - 2026)

Ligand Pharmaceuticals has disclosed Cash & Equivalents across 17 years of filings, most recently posting $115.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $115.1 million, up 139.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (up 139.8% YoY), and the FY2025 annual result was $174.9 million, up 141.92% from the prior year.
• Cash & Equivalents came in at $115.1 million for Q1 2026 at Ligand Pharmaceuticals, down from $174.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $174.9 million in Q4 2025 to a low of $4.1 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $48.0 million (2025), against an average of $57.5 million.
• Across the five-year window, Cash & Equivalents plunged 82.43% in 2022 and surged 491.8% in 2023, its largest moves.
• Ligand Pharmaceuticals' Cash & Equivalents stood at $45.0 million in 2022, then tumbled by 49.0% to $23.0 million in 2023, then surged by 215.01% to $72.3 million in 2024, then soared by 141.92% to $174.9 million in 2025, then plunged by 34.21% to $115.1 million in 2026.
• The last three Cash & Equivalents figures came in at $115.1 million (Q1 2026), $174.9 million (Q4 2025), and $139.4 million (Q3 2025), per Business Quant data.